Buy or sell Nucleix stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Nucleix Stock

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests.

About Nucleix Stock

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Funding History

January 2015$50K
May 2016$3.0M
July 2018$2.5M
April 2021$55.0M
January 2022$22.0M

Management

Co-founder, VP Software & Analytics

Adam Wasserstrom

VP Research & Co-founder

Danny Frumkin

Chief Executive Officer

Chris Hibberd

Member of Board of Directors

Dan J. Gelvan

Chief Financial Officer

W. Todd Myers

Executive Chairman

Chris Hibberd

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 280K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo